生物制药公司阿尔凯默斯(ALKS)今日盘前大涨11.61%,引发市场关注。从公司最新财报来看,其业绩表现优异或是股价上涨的主因。
阿尔凯默斯2024财年调整后每股收益达2.92美元,超出分析师预期的2.66美元,同比增长24.79%;全年销售额15.6亿美元,亦超出预期15.1亿美元,同比大增93.66%。此外,公司第四季度营收和获利也均超出市场预期。
展望2025年,阿尔凯默斯预计总收入将介于13.4亿至14.3亿美元,主力产品VIVITROL、ARISTADAi和LYBALVI净销售额合计达到8.15亿至8.35亿美元。公司在研发、营销方面支出也将有所增长,但净利润和调整后EBITDA均保持较高水平。可喜的财务表现和前景预期,支撑了阿尔凯默斯股价今日走高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.